Annotation Detail for TICAM2

Basic Information
Top
Pathway ID | Pathway Name |
---|
hsa04620 | Toll-like receptor signaling pathway |
Pathway ID | Pathway Name |
---|
P00054 | Toll receptor signaling pathway |
Chemical ID |
Chemical Name |
Interaction |
Interaction Action |
Publication |
---|
D001564 |
Benzo(a)pyrene |
Benzo(a)pyrene results in increased expression of TICAM2 mRNA | increases expression | 20106945
|
D015123 |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of TICAM2 mRNA | decreases expression | 20382639
|
D016572 |
Cyclosporine |
Cyclosporine results in increased expression of TICAM2 mRNA | increases expression | 20106945
|
C010327 |
salinomycin |
salinomycin results in decreased expression of TICAM2 mRNA | decreases expression | 19682730
|
Disease ID |
Disease Name |
Direct Evidence |
Inference Chemical Name |
Inference Score |
Publication |
---|
MESH:D000230 |
Adenocarcinoma |
|
Benzo(a)pyrene |
2.06 | 20127859 20464547 |
MESH:D000236 |
Adenoma |
|
Benzo(a)pyrene |
2.86 | 6695378 |
MESH:D017544 |
Aortic Aneurysm, Abdominal |
|
Benzo(a)pyrene |
4.64 | 19183758 |
MESH:D001943 |
Breast Neoplasms |
|
Benzo(a)pyrene |
2.46 | 17474063 20146248 |
MESH:D001943 |
Breast Neoplasms |
|
salinomycin |
2.46 | 19682730 |
MESH:D002294 |
Carcinoma, Squamous Cell |
|
Benzo(a)pyrene |
2.13 | 20419170 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
7.44 | 20889678 |
MESH:D002471 |
Cell Transformation, Neoplastic |
|
Cyclosporine |
7.44 | 12371664 |
MESH:D002779 |
Cholestasis |
|
Cyclosporine |
3.21 | 19486331 |
MESH:D004938 |
Esophageal Neoplasms |
|
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide |
4.62 | 20426865 |
MESH:D004938 |
Esophageal Neoplasms |
|
Benzo(a)pyrene |
4.62 | 16530937 |
MESH:D005234 |
Fatty Liver |
|
Cyclosporine |
3.28 | 19224547 |
MESH:D005355 |
Fibrosis |
|
Cyclosporine |
3.70 | 12168785 12639820 |
MESH:D005885 |
Gingival Hyperplasia |
|
Cyclosporine |
4.85 | 8708960 |
MESH:D006330 |
Heart Defects, Congenital |
|
Benzo(a)pyrene |
2.83 | 20471113 |
MESH:D006457 |
Hemoglobinuria, Paroxysmal |
|
Cyclosporine |
5.05 | 15720958 |
MESH:D006973 |
Hypertension |
|
Cyclosporine |
2.21 | 10903974 |
MESH:D007638 |
Keratoconjunctivitis Sicca |
|
Cyclosporine |
5.16 | 15604871 |
MESH:D007674 |
Kidney Diseases |
|
Cyclosporine |
2.54 | 8314463 10903974 18776723 |
MESH:D007680 |
Kidney Neoplasms |
|
Cyclosporine |
3.08 | 12371664 |
MESH:D008113 |
Liver Neoplasms |
|
Benzo(a)pyrene |
2.15 | 21137059 20195826 |
MESH:D008175 |
Lung Neoplasms |
|
Benzo(a)pyrene |
1.57 | 17053015 20464547 18520028 20064080 20135361 20869020 6695378 18569708 18816296 |
MESH:D008325 |
Mammary Neoplasms, Experimental |
|
salinomycin |
4.00 | 19682730 |
MESH:D008664 |
Metal Metabolism, Inborn Errors |
|
Cyclosporine |
5.51 | 16801185 |
MESH:D009062 |
Mouth Neoplasms |
|
Benzo(a)pyrene |
3.50 | 16381670 |
MESH:D009369 |
Neoplasms |
|
Benzo(a)pyrene |
2.33 | 11141357 |
MESH:D009402 |
Nephrosis, Lipoid |
|
Cyclosporine |
5.16 | 17954296 |
MESH:D009404 |
Nephrotic Syndrome |
|
Cyclosporine |
3.65 | 19348381 18481113 |
MESH:D011230 |
Precancerous Conditions |
|
Cyclosporine |
3.59 | 12371664 |
MESH:D011471 |
Prostatic Neoplasms |
|
Benzo(a)pyrene |
2.91 | 17292933 |
MESH:D011565 |
Psoriasis |
|
Cyclosporine |
2.33 | 16882103 |
MESH:D012878 |
Skin Neoplasms |
|
Benzo(a)pyrene |
2.52 | 10029692 19755658 |
MESH:D013274 |
Stomach Neoplasms |
|
Benzo(a)pyrene |
1.56 | 20155912 2093021 |
MESH:D001749 |
Urinary Bladder Neoplasms |
|
Benzo(a)pyrene |
2.30 | 17053015 |
MESH:D014605 |
Uveitis |
|
Cyclosporine |
4.71 | 1336536 |
MESH:D014985 |
Xerophthalmia |
|
Cyclosporine |
5.16 | 17120751 |
Pathway ID |
Pathway Name |
---|
REACT:6900 |
Signaling in Immune system |
KEGG:04620 |
Toll-like receptor signaling pathway |